AI Science Tracker
EN

Elucidating AML ribosome biogenesis reshaping prognostic assessment and immune microenvironment integrated single-cell and bulk RNA analysis.

Department of Blood Transfusion, The Third Affiliated Hospital of Wenzhou Medical University, Rui'an, China · 28 Nov 2025 · medicine

Discovery

Elucidating AML ribosome biogenesis reshaping prognostic assessment and immune microenvironment integrated single-cell and bulk RNA analysis.

Source check: Source checked. Not independent scientific confirmation.

Finding: Random-survival-forest feature selection produced an AML ribosome-biogenesis signature associated with survival across independent cohorts. Published in Frontiers in Immunology.

Technology: The source compares 81 model combinations and validates in six independent cohorts, with qPCR/Western-blot checks reported separately.

Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.

AI contribution
The source compares 81 model combinations and validates in six independent cohorts, with qPCR/Western-blot checks reported separately.
Test and result
Primary Results describe the specific comparator, cohort or experimental check; limitations are stated narrowly.
Limitation / still unknown
External replication and real-world or clinical benefit were not established by the reviewed study
Evidence sources and annotation context

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

Evidence sources: https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2025.1644671/full · https://europepmc.org/article/MED/41394823 · https://pubmed.ncbi.nlm.nih.gov/41394823/

Source checked · editorial details

The source page was checked against this entry. Independent confirmation is not assessed by this label.

Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.

Review date: 22 Nov 2026. Review scope: Primary result-bearing material for the stated method, result and evaluation, with bibliographic version information..

No follow-up recorded; this is not a claim that no follow-up exists. Follow-up review scope and date are not recorded. No source-supported relationships recorded.

Editorial assessment: Impact 3/5 · Validation 2/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Open in the full catalog for filters, charts and related discoveries. Browse medicine discoveries.